Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Characterization of patient-derived xenograft models of myxoid liposarcoma either sentitive or resistant to trabectedin

ABSTRACT: Two patient-derived xenograft model of myxoid liposarcoma one sensitive and one resistant to trabectedin. The aim of the study was to study the resistance to the drug.

PROVIDER: EGAS00001003715 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

Transcriptional profiling of patient-derived xenograft models of myxoid liposarcoma either responsive or resistant to trabectedin treatment.

Project description:Transcriptional profiling of patient-derived xenograft models of myxoid liposarcoma with either FUS-CHOP type I, named as ML017, or FUS-CHOP type III, named as ML006. Both ML017 and ML006 are responsive to trabectedin treatment, while model ML017/ET has aquired resistance to the drug. Samples are either under untreated conditions, or treated either with trabectedin or pioglitazone or both.

2020-01-10 | E-MTAB-8632 | biostudies-arrayexpress

Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors.

Project description: Not available

| S-EPMC5652737 | biostudies-literature

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.

Project description: Not available

| S-EPMC8384880 | biostudies-literature

Establishment and characterization of testicular cancer patient-derived xenograft (PDX) models [RNA-seq]

Project description:Testicular cancer (TC) is the most common solid tumour in young men. While cisplatin-based chemotherapy is highly effective in TC patients, chemoresistance still accounts for 10% of disease-related deaths. Pre-clinical models that faithfully reflect patient tumours are needed to assist in target discovery and drug development. Tumour pieces from eight TC patients were subcutaneously implanted in NOD scid gamma (NSG) mice. Three patient-derived xenograft (PDX) models of TC, including one chemoresistant model, were established containing yolk sac tumour and teratoma components. Whole-exome sequencing, copy number variation analysis and RNA-sequencing was performed on these TP53 wild type PDX tumours to assess the effects of passaging, showing high concordance of molecular features between passages.

2020-07-29 | GSE152270 | GEO

Establishment and characterization of testicular cancer patient-derived xenograft (PDX) models [SNP array]

2020-07-29 | GSE155262 | GEO

Establishment of palbociclib resistant metastatic breast cancer patient-derived xenograft models

Project description:Identify therapeutic vulnerabilities of palbociclib resistance in metastatic breast cancer patient-derived xenograft models and identify key biomarkers that correlate with development of resistance to inform new treatment directions

2023-07-10 | GSE229235 | GEO

Prioritizing therapeutic targets using patient-derived xenograft models.

Project description: Not available

| S-EPMC4433556 | biostudies-literature

Establishment and characterization of testicular cancer patient-derived xenograft (PDX) models

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-07-29 | GSE155277 | GEO

Novel dedifferentiated liposarcoma xenograft models reveal PTEN down regulation as a malignant signature and response to PI3K pathway inhibition

Project description:Liposarcoma is a type of soft tissue sarcoma, exhibiting poor survival and a high recurrence rate. Treatment is generally limited to surgery and radiation, emphasizing the need to understand this disease. Because very few in vivo and in vitro models can reproducibly recapitulate the human disease, we generated several xenograft models from surgically resected human dedifferentiated liposarcoma. Our study demonstrates that all xenografts recapitulate morphologic and gene expression characteristics of the patient tumors after continuous in vivo passages. Importantly, xenograftability is directly correlated with disease specific survival of liposarcoma patients. When treated with the PI3K/AKT/mTOR pathway inhibitor rapamycin alone or in combination with the multi-kinase inhibitor sorafenib, all xenografts responded with increased lipid content and a more differentiated gene expression profile. One-color arrays: Vehicle vs combination (rapamycin & sorafenib) treatment for 2 separate dedifferentiated liposarcoma xenografts. Two-color arrays: Comparison of patient tumor, several passages of xenograft generated from that tumor, and cells cultured from xenografted tumors.

2012-12-19 | E-GEOD-42975 | biostudies-arrayexpress

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.

Project description: Not available

| S-EPMC4818716 | biostudies-literature